Medicines Co. makes grounds in case against Patent Office
The U.S. District Court for the Eastern District of Virginia has granted the Medicines Company's motion for summary judgment and ordered the U.S. Patent and Trademark Office "to consider the Medicine[s] Company's patent term extension application timely filed."
In the ongoing battle, the court awarded summary judgment to the company in its lawsuit challenging the U.S. Patent and Trademark Office denial of the application for an extension of the term of U.S. Patent No. 5,196,404, the U.S. composition of matter patent that covers bivalirudin (Angiomax), The Medicines Company said.
In the ongoing battle, the court awarded summary judgment to the company in its lawsuit challenging the U.S. Patent and Trademark Office denial of the application for an extension of the term of U.S. Patent No. 5,196,404, the U.S. composition of matter patent that covers bivalirudin (Angiomax), The Medicines Company said.